08 September 2026: PILA PHARMA AB (publ) (FN STO: PILA), a clinical stage biotech company pioneering development of an oral TRPV1-antagonist as a potential first-in-class treatment for obesity and diabetes, today informs that the recordings from the last few weeks activities and presentations, are now all published online.

___________

H1 Review - Infront Direkt Studios (Live Broadcast Recording – Stockholm, Sweden)
Recorded Thursday 27 August 11:30 CET (ENGLISH)
CEO Gustav H. Gram visits Direkt Studios in Stockholm on the Company’s report release day, to discuss the the first half year of 2026 and the significant recent development with the Company’s announcing it has regulatory approval for a new longer clinical trial in people living with obesity with the company’s oral small molecule TRPV1 antagonist, a key step in the clinical development.

H1 Sitdown Interview – Finwire (Recording – Stockholm, Sweden)
Recorded Thursday 27 August 13:00 CET (ENGLISH)
CEO Gustav H. Gram sits down with Finwire, to comment on the significant development with the Company’s recently announced regulatory approval for a new longer clinical trial in people living with obesity with the company’s oral small molecule TRPV1 antagonist and the steps forward.

H1 and Clinical Development Interview – BioStock (Recording – Lund, Sweden)
Recorded Monday 31 August 10:00 CET (ENGLISH)
CEO Gustav H. Gram visits the BioStock Studio in Lund, Sweden to discuss the company’s report for the first half year of 2026 and the significant development of the recently announced regulatory approval for a new longer clinical trial in people living with obesity with the company’s oral small molecule TRPV1 antagonist.

ProInvestor with Helge Larsen (ProInvestor Studio - Denmark)
Recorded Thursday 03 September 11:30 CET (DANISH)
CSO Dorte X. Gram sits down with Helge Larsen from Danish biotech and pharma investment community ProInvestor, to discuss the significant development with the Company’s recently announced regulatory approval for a new longer clinical trial in people living with obesity with the company’s oral small molecule TRPV1 antagonist.

___________

More events are subject to being announced! To always stay up to date on events and where to meet us, please see our website: https://www.pilapharma.com/

For more information:
Gustav H. Gram, CEO
ghg@pilapharma.com

PILA PHARMA’s share ticker PILA is subject to trade on Nasdaq First North Growth Market, Sweden with Aqurat Fondkommission AB as Certified Adviser. Contact: M: ca@aqurat.se - T: +46 (0)8 684 05 800

About PILA PHARMA AB (Publ)

PILA PHARMA AB is a Swedish clinical stage biotech company based in Malmö, Sweden. The aim of the company is to develop TRPV1 antagonists as a novel treatment of obesity and diabetes. The Company owns a TRPV1 asset with data and chemical entities including the clinical development candidate XEN-D0501. In July 2022, the Company was moreover awarded orphan drug designation ("ODD") for XEN-D0501 as a treatment for the painful rare disease erythromelalgia.

Attachments
PILA PHARMA: ALL RECENT H1 REPORT AND MANAGEMENT INTERVIEWS NOW ONLINE